FDA Endorses Truqap Prostate Cancer Therapy for PTEN-Deficient Cases

Truqap Prostate Cancer Therapy gains key backing from FDA advisors for PTEN-deficient metastatic hormone-sensitive prostate cancer, following strong data from the pivotal trial that demonstrated meaningful delays in disease progression.

ODAC Backs Targeted Therapy

The US Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) has endorsed a favourable benefit-risk profile for AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) for PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC). This recommendation stems directly from the CAPItello-281 Phase III trial, in which the committee voted 7 to 1 (with one abstention) in support of the regimen. The decision highlights the combination’s statistically significant improvement in radiographic progression-free survival (rPFS) and its potential to address a defined patient subgroup with aggressive disease and limited options.

Trial Shows Clear Benefits

Primary analysis results demonstrated a 19% reduction in the risk of radiographic disease progression or death, translating to a clinically meaningful 7.5-month gain in median rPFS (33.2 months versus 25.7 months; hazard ratio [HR] 0.81; 95% confidence interval [CI] 0.66-0.98; p=0.034) compared with abiraterone plus ADT and placebo. Consistent benefits extended to key secondary endpoints, including prolonged time to castration resistance (29.5 versus 22.0 months; HR 0.77) and delayed prostate-specific antigen progression, alongside improvements in symptomatic skeletal event-free survival. Interim overall survival data numerically favoured the Truqap Prostate Cancer Therapy arm, although maturity is pending, while the safety profile remained aligned with the known effects of each component, albeit with higher rates of Grade 3 or higher adverse events such as rash and hyperglycaemia.

Focused Patient Group

CAPItello-281 employed a double-blind, randomised Phase III design that prospectively enrolled 1,012 patients with histologically confirmed de novo mHSPC and centrally verified PTEN deficiency, comparing the investigational combination against abiraterone and ADT plus placebo. The primary endpoint focused on investigator-assessed rPFS, with overall survival designated as a key secondary endpoint; this methodology directly addressed the biological role of PTEN loss in driving PI3K/AKT pathway dysregulation and poorer prognosis. By restricting enrolment to the PTEN-deficient subset, which comprises approximately one in four mHSPC cases, the trial isolated a population experiencing rapid progression to castration resistance and elevated mortality risk.

Access and Reimbursement Outlook

The ODAC’s recognition of substantial unmet need in PTEN-deficient mHSPC supports potential expansion of targeted therapy access, which could influence health technology assessment decisions by demonstrating value through delayed disease progression and reduced symptomatic events. Such outcomes may inform pricing negotiations and reimbursement strategies by quantifying clinical benefit in a biomarker-defined population, thereby facilitating earlier integration into treatment pathways. As regulatory reviews proceed in the European Union and elsewhere, these findings underscore opportunities for health economics and outcomes research (HEOR) frameworks to model long-term resource utilisation and patient quality-of-life gains associated with first-in-class AKT inhibition in this setting.